Kurzfassung

A phase II, single-arm study to investigate the efficacy and safety of the antibody drug conjugate GSK2857916 in participants with relapsed/refractory Multiple Myeloma who have failed prior treatment with an Anti-CD38 antibody (DREAMM 2)